UpSMART Accelerator Programme.
In 2019 the Digital Cancer Research team within the CRUK Manchester Institute Cancer Biomarker Centre, along with our EU colleagues, including those from Fondazione IRCCS Istituto Nazionale Tumori, Milan and Vall d’Hebron, Barcelona were awarded a CRUK Accelerator Award to enable SMART Experimental Cancer Medicine Trials. The ambition of this programme, entitled “UpSMART”, is to ‘digitalise up’ experimental cancer medicine centres across the UK, Italy & Spain, providing clinical teams with digital tools for real-time access to a wealth of patient data allowing faster decision making. The UpSMART consortium consists of 23 participating centres across Experimental Cancer Medicine Centres (ECMCs) in the UK and Early Drug Development Units (EDDUs) in Spain and Italy. Furthermore, 2 collaborating centres in France have been onboarded to UpSMART and are actively involved in advancing various aspects of the programme.
The Accelerator Award funding means that the consortium can use digital healthcare products to enable data acquisition and data interpretation and create digitally enabled Phase 1 centres able to conduct technology clinical trials. The UpSMART Accelerator programme will test existing digital tools within 23 Phase 1 Units that have joined this aspiring, timely programme. UpSMART will be developing and providing all clinical sites with free to use access to new digital healthcare technology approaches and improvements in trials that enable patients access to tomorrow’s medicines today. Our goal is for these and other digital healthcare products to be shared and implemented more widely together with training in digital healthcare product approaches.
For further details on the UpSMART Accelerator Award and our ambition to drive digital innovation in early phase cancer clinical trials, please click on the link to our publication in Digital Medicine here.
The eTARGET tool has revolutionised MTB. It facilitated continued patient review during the restrictions imposed by COVID-19 and has permitted smooth transition to national MTBs. Mutation frequency data is easily accessible to all trial investigators and the addition of the trial finder tool has enabled rapid national matching to clinical trials.
UpSMART Team
Professor Caroline Dive
Principal Investigator
Dr Louise Carter
Senior Clinical Lecturer in Experimental Cancer Medicine, University of Manchester; Honorary Consultant in Medical Oncology, The Christie
Dr Donna Graham
Medical Oncologist, Digital Cancer Research team & The Christie
Fouziah Butt
Principal Business Analyst, Digital Cancer Research team
Dr Elena Garralda
Medical Oncologist, Co-Investigator, VHIO
Berta Colldeforns Riera
Project Manager, VHIO
Professor Filippo de Braud
Medical Oncologist, Co-Investigator, INT
Dr Silvia Damian
Medical Oncologist, INT
Andrea Villa
Project Manager, INT
Luca Agnelli
Data Scientist, INT
Marcello Carapezza
IT Specialist, INT
Participating centres across Europe
Contact
Digital Cancer Research Team,
Cancer Research UK Manchester Institute
The University of Manchester
Wilmslow Road
Manchester
M20 4BX
QUICK LINKS
Home
About
Disclaimer: The digital health products created through UpSMART are for research use only as regulatory approval has not yet been sought. Please contact us if you wish to use any of the UpSMART products in a research study.
CONTACT
Digital Cancer Research team,
Cancer Research UK Manchester Institute
The University of Manchester
Wilmslow Road
Manchester
M20 4BX
